New York, March 31, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Non-alcoholic Steatohepatitis (NASH) Industry" - https://www.reportlinker.com/p06044755/?utm_source=GNW
In addition to being a global intelligence exchange platform, MarketGlass™ is a powerful knowledge center that delivers dynamic project-focused market intelligence. Client companies will have complete insider access to the project Data stack.
- Interactive peer-to-peer and enterprise-to-enterprise ideation and market intelligence exchange is facilitated via a robust, secure, and validated process. The process draws from uniquely qualified project-specific and geographically focused executives overseeing business development, marketing and sales operations.
- Trends & Factors - Identifying and validating local trends and factors driving each competitive marketplace. These factors include pricing variances, market trajectories, Covid-19 impact and recovery, locally active leading brands, and other parameters impacting the region in the short to medium term such as supply chain realignments.
- Mobile Access & App - Our mobile version of the report may be accessed via our mobile app or directly for a full mobile experience.
- Complimentary Updates - for one year. At least one update in 12-month period is normal and anytime there’s a significant change affecting the market dynamics.
- Bespoke Updates & Team Collaborations - Clients may build a bespoke version of our report with peers on our MarketGlass™ platform which enables multidimensional data simulations.
- Knowledge Center - clients have full-stack data access for project data they support or purchase including primary research engagement stats, companies and executives.
Abstract:
- Global Non-alcoholic Steatohepatitis (NASH) Market to Reach $39.5 Billion by 2027
- Amid the COVID-19 crisis, the global market for Non-alcoholic Steatohepatitis (NASH) estimated at US$2 Billion in the year 2020, is projected to reach a revised size of US$39.5 Billion by 2027, growing at a CAGR of 53.2% over the analysis period 2020-2027. Vitamin E & Pioglitazone, one of the segments analyzed in the report, is projected to record a 46.1% CAGR and reach US$16.5 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Obeticholic Acid (OCA) segment is readjusted to a revised 44.4% CAGR for the next 7-year period.
- The U.S. Market is Estimated at $606.7 Million, While China is Forecast to Grow at 50.5% CAGR
- The Non-alcoholic Steatohepatitis (NASH) market in the U.S. is estimated at US$606.7 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$6.4 Billion by the year 2027 trailing a CAGR of 50.9% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 46.5% and 45.1% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 35.5% CAGR.
- Elafibranor Segment to Record 72.9% CAGR
- In the global Elafibranor segment, USA, Canada, Japan, China and Europe will drive the 72.9% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$208.6 Million in the year 2020 will reach a projected size of US$9.6 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$5 Billion by the year 2027.
- Select Competitors (Total 41 Featured) -
- AstraZeneca PLC
- Conatus Pharmaceuticals Inc.
- Galmed Pharmaceuticals Ltd.
- Genfit SA
- Gilead Sciences, Inc.
- Immuron Ltd.
- Intercept Pharmaceuticals, Inc.
- Zydus Cadila
Read the full report: https://www.reportlinker.com/p06044755/?utm_source=GNW
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
Table 1: World Current & Future Analysis for Non-alcoholic
Steatohepatitis (NASH) by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR
Table 2: World Historic Review for Non-alcoholic
Steatohepatitis (NASH) by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR
Table 3: World 15-Year Perspective for Non-alcoholic
Steatohepatitis (NASH) by Geographic Region - Percentage
Breakdown of Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets for Years 2012, 2020 &
2027
Table 4: World Current & Future Analysis for Vitamin E &
Pioglitazone by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2020 through
2027 and % CAGR
Table 5: World Historic Review for Vitamin E & Pioglitazone by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR
Table 6: World 15-Year Perspective for Vitamin E & Pioglitazone
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027
Table 7: World Current & Future Analysis for Obeticholic Acid
(OCA) by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2020 through 2027 and
% CAGR
Table 8: World Historic Review for Obeticholic Acid (OCA) by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR
Table 9: World 15-Year Perspective for Obeticholic Acid (OCA)
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027
Table 10: World Current & Future Analysis for Elafibranor by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2020 through 2027 and
% CAGR
Table 11: World Historic Review for Elafibranor by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2012 through 2019 and % CAGR
Table 12: World 15-Year Perspective for Elafibranor by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027
Table 13: World Current & Future Analysis for Selonsertib &
Cenicriviroc by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2020 through
2027 and % CAGR
Table 14: World Historic Review for Selonsertib & Cenicriviroc
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR
Table 15: World 15-Year Perspective for Selonsertib &
Cenicriviroc by Geographic Region - Percentage Breakdown of
Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific
and Rest of World for Years 2012, 2020 & 2027
Table 16: World Current & Future Analysis for Hospital Pharmacy
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2020 through 2027 and
% CAGR
Table 17: World Historic Review for Hospital Pharmacy by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR
Table 18: World 15-Year Perspective for Hospital Pharmacy by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027
Table 19: World Current & Future Analysis for Online Provider
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2020 through 2027 and
% CAGR
Table 20: World Historic Review for Online Provider by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR
Table 21: World 15-Year Perspective for Online Provider by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027
Table 22: World Current & Future Analysis for Retail Pharmacy
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2020 through 2027 and
% CAGR
Table 23: World Historic Review for Retail Pharmacy by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR
Table 24: World 15-Year Perspective for Retail Pharmacy by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027
III. MARKET ANALYSIS
UNITED STATES
Table 25: USA Current & Future Analysis for Non-alcoholic
Steatohepatitis (NASH) by Drug Type - Vitamin E & Pioglitazone,
Obeticholic Acid (OCA), Elafibranor and Selonsertib &
Cenicriviroc - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR
Table 26: USA Historic Review for Non-alcoholic Steatohepatitis
(NASH) by Drug Type - Vitamin E & Pioglitazone, Obeticholic
Acid (OCA), Elafibranor and Selonsertib & Cenicriviroc Markets -
Independent Analysis of Annual Sales in US$ Thousand for
Years 2012 through 2019 and % CAGR
Table 27: USA 15-Year Perspective for Non-alcoholic
Steatohepatitis (NASH) by Drug Type - Percentage Breakdown of
Value Sales for Vitamin E & Pioglitazone, Obeticholic Acid
(OCA), Elafibranor and Selonsertib & Cenicriviroc for the Years
2012, 2020 & 2027
Table 28: USA Current & Future Analysis for Non-alcoholic
Steatohepatitis (NASH) by Sales Channel - Hospital Pharmacy,
Online Provider and Retail Pharmacy - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR
Table 29: USA Historic Review for Non-alcoholic Steatohepatitis
(NASH) by Sales Channel - Hospital Pharmacy, Online Provider
and Retail Pharmacy Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Table 30: USA 15-Year Perspective for Non-alcoholic
Steatohepatitis (NASH) by Sales Channel - Percentage Breakdown
of Value Sales for Hospital Pharmacy, Online Provider and
Retail Pharmacy for the Years 2012, 2020 & 2027
CANADA
Table 31: Canada Current & Future Analysis for Non-alcoholic
Steatohepatitis (NASH) by Drug Type - Vitamin E & Pioglitazone,
Obeticholic Acid (OCA), Elafibranor and Selonsertib &
Cenicriviroc - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR
Table 32: Canada Historic Review for Non-alcoholic
Steatohepatitis (NASH) by Drug Type - Vitamin E & Pioglitazone,
Obeticholic Acid (OCA), Elafibranor and Selonsertib &
Cenicriviroc Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2012 through 2019 and % CAGR
Table 33: Canada 15-Year Perspective for Non-alcoholic
Steatohepatitis (NASH) by Drug Type - Percentage Breakdown of
Value Sales for Vitamin E & Pioglitazone, Obeticholic Acid
(OCA), Elafibranor and Selonsertib & Cenicriviroc for the Years
2012, 2020 & 2027
Table 34: Canada Current & Future Analysis for Non-alcoholic
Steatohepatitis (NASH) by Sales Channel - Hospital Pharmacy,
Online Provider and Retail Pharmacy - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR
Table 35: Canada Historic Review for Non-alcoholic
Steatohepatitis (NASH) by Sales Channel - Hospital Pharmacy,
Online Provider and Retail Pharmacy Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR
Table 36: Canada 15-Year Perspective for Non-alcoholic
Steatohepatitis (NASH) by Sales Channel - Percentage Breakdown
of Value Sales for Hospital Pharmacy, Online Provider and
Retail Pharmacy for the Years 2012, 2020 & 2027
JAPAN
Table 37: Japan Current & Future Analysis for Non-alcoholic
Steatohepatitis (NASH) by Drug Type - Vitamin E & Pioglitazone,
Obeticholic Acid (OCA), Elafibranor and Selonsertib &
Cenicriviroc - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR
Table 38: Japan Historic Review for Non-alcoholic
Steatohepatitis (NASH) by Drug Type - Vitamin E & Pioglitazone,
Obeticholic Acid (OCA), Elafibranor and Selonsertib &
Cenicriviroc Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2012 through 2019 and % CAGR
Table 39: Japan 15-Year Perspective for Non-alcoholic
Steatohepatitis (NASH) by Drug Type - Percentage Breakdown of
Value Sales for Vitamin E & Pioglitazone, Obeticholic Acid
(OCA), Elafibranor and Selonsertib & Cenicriviroc for the Years
2012, 2020 & 2027
Table 40: Japan Current & Future Analysis for Non-alcoholic
Steatohepatitis (NASH) by Sales Channel - Hospital Pharmacy,
Online Provider and Retail Pharmacy - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR
Table 41: Japan Historic Review for Non-alcoholic
Steatohepatitis (NASH) by Sales Channel - Hospital Pharmacy,
Online Provider and Retail Pharmacy Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR
Table 42: Japan 15-Year Perspective for Non-alcoholic
Steatohepatitis (NASH) by Sales Channel - Percentage Breakdown
of Value Sales for Hospital Pharmacy, Online Provider and
Retail Pharmacy for the Years 2012, 2020 & 2027
CHINA
Table 43: China Current & Future Analysis for Non-alcoholic
Steatohepatitis (NASH) by Drug Type - Vitamin E & Pioglitazone,
Obeticholic Acid (OCA), Elafibranor and Selonsertib &
Cenicriviroc - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR
Table 44: China Historic Review for Non-alcoholic
Steatohepatitis (NASH) by Drug Type - Vitamin E & Pioglitazone,
Obeticholic Acid (OCA), Elafibranor and Selonsertib &
Cenicriviroc Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2012 through 2019 and % CAGR
Table 45: China 15-Year Perspective for Non-alcoholic
Steatohepatitis (NASH) by Drug Type - Percentage Breakdown of
Value Sales for Vitamin E & Pioglitazone, Obeticholic Acid
(OCA), Elafibranor and Selonsertib & Cenicriviroc for the Years
2012, 2020 & 2027
Table 46: China Current & Future Analysis for Non-alcoholic
Steatohepatitis (NASH) by Sales Channel - Hospital Pharmacy,
Online Provider and Retail Pharmacy - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR
Table 47: China Historic Review for Non-alcoholic
Steatohepatitis (NASH) by Sales Channel - Hospital Pharmacy,
Online Provider and Retail Pharmacy Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR
Table 48: China 15-Year Perspective for Non-alcoholic
Steatohepatitis (NASH) by Sales Channel - Percentage Breakdown
of Value Sales for Hospital Pharmacy, Online Provider and
Retail Pharmacy for the Years 2012, 2020 & 2027
EUROPE
Table 49: Europe Current & Future Analysis for Non-alcoholic
Steatohepatitis (NASH) by Geographic Region - France, Germany,
Italy, UK and Rest of Europe Markets - Independent Analysis of
Annual Sales in US$ Thousand for Years 2020 through 2027 and %
CAGR
Table 50: Europe Historic Review for Non-alcoholic
Steatohepatitis (NASH) by Geographic Region - France, Germany,
Italy, UK and Rest of Europe Markets - Independent Analysis of
Annual Sales in US$ Thousand for Years 2012 through 2019 and %
CAGR
Table 51: Europe 15-Year Perspective for Non-alcoholic
Steatohepatitis (NASH) by Geographic Region - Percentage
Breakdown of Value Sales for France, Germany, Italy, UK and
Rest of Europe Markets for Years 2012, 2020 & 2027
Table 52: Europe Current & Future Analysis for Non-alcoholic
Steatohepatitis (NASH) by Drug Type - Vitamin E & Pioglitazone,
Obeticholic Acid (OCA), Elafibranor and Selonsertib &
Cenicriviroc - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR
Table 53: Europe Historic Review for Non-alcoholic
Steatohepatitis (NASH) by Drug Type - Vitamin E & Pioglitazone,
Obeticholic Acid (OCA), Elafibranor and Selonsertib &
Cenicriviroc Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2012 through 2019 and % CAGR
Table 54: Europe 15-Year Perspective for Non-alcoholic
Steatohepatitis (NASH) by Drug Type - Percentage Breakdown of
Value Sales for Vitamin E & Pioglitazone, Obeticholic Acid
(OCA), Elafibranor and Selonsertib & Cenicriviroc for the Years
2012, 2020 & 2027
Table 55: Europe Current & Future Analysis for Non-alcoholic
Steatohepatitis (NASH) by Sales Channel - Hospital Pharmacy,
Online Provider and Retail Pharmacy - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR
Table 56: Europe Historic Review for Non-alcoholic
Steatohepatitis (NASH) by Sales Channel - Hospital Pharmacy,
Online Provider and Retail Pharmacy Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR
Table 57: Europe 15-Year Perspective for Non-alcoholic
Steatohepatitis (NASH) by Sales Channel - Percentage Breakdown
of Value Sales for Hospital Pharmacy, Online Provider and
Retail Pharmacy for the Years 2012, 2020 & 2027
FRANCE
Table 58: France Current & Future Analysis for Non-alcoholic
Steatohepatitis (NASH) by Drug Type - Vitamin E & Pioglitazone,
Obeticholic Acid (OCA), Elafibranor and Selonsertib &
Cenicriviroc - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR
Table 59: France Historic Review for Non-alcoholic
Steatohepatitis (NASH) by Drug Type - Vitamin E & Pioglitazone,
Obeticholic Acid (OCA), Elafibranor and Selonsertib &
Cenicriviroc Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2012 through 2019 and % CAGR
Table 60: France 15-Year Perspective for Non-alcoholic
Steatohepatitis (NASH) by Drug Type - Percentage Breakdown of
Value Sales for Vitamin E & Pioglitazone, Obeticholic Acid
(OCA), Elafibranor and Selonsertib & Cenicriviroc for the Years
2012, 2020 & 2027
Table 61: France Current & Future Analysis for Non-alcoholic
Steatohepatitis (NASH) by Sales Channel - Hospital Pharmacy,
Online Provider and Retail Pharmacy - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR
Table 62: France Historic Review for Non-alcoholic
Steatohepatitis (NASH) by Sales Channel - Hospital Pharmacy,
Online Provider and Retail Pharmacy Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR
Table 63: France 15-Year Perspective for Non-alcoholic
Steatohepatitis (NASH) by Sales Channel - Percentage Breakdown
of Value Sales for Hospital Pharmacy, Online Provider and
Retail Pharmacy for the Years 2012, 2020 & 2027
GERMANY
Table 64: Germany Current & Future Analysis for Non-alcoholic
Steatohepatitis (NASH) by Drug Type - Vitamin E & Pioglitazone,
Obeticholic Acid (OCA), Elafibranor and Selonsertib &
Cenicriviroc - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR
Table 65: Germany Historic Review for Non-alcoholic
Steatohepatitis (NASH) by Drug Type - Vitamin E & Pioglitazone,
Obeticholic Acid (OCA), Elafibranor and Selonsertib &
Cenicriviroc Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2012 through 2019 and % CAGR
Table 66: Germany 15-Year Perspective for Non-alcoholic
Steatohepatitis (NASH) by Drug Type - Percentage Breakdown of
Value Sales for Vitamin E & Pioglitazone, Obeticholic Acid
(OCA), Elafibranor and Selonsertib & Cenicriviroc for the Years
2012, 2020 & 2027
Table 67: Germany Current & Future Analysis for Non-alcoholic
Steatohepatitis (NASH) by Sales Channel - Hospital Pharmacy,
Online Provider and Retail Pharmacy - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR
Table 68: Germany Historic Review for Non-alcoholic
Steatohepatitis (NASH) by Sales Channel - Hospital Pharmacy,
Online Provider and Retail Pharmacy Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR
Table 69: Germany 15-Year Perspective for Non-alcoholic
Steatohepatitis (NASH) by Sales Channel - Percentage Breakdown
of Value Sales for Hospital Pharmacy, Online Provider and
Retail Pharmacy for the Years 2012, 2020 & 2027
ITALY
Table 70: Italy Current & Future Analysis for Non-alcoholic
Steatohepatitis (NASH) by Drug Type - Vitamin E & Pioglitazone,
Obeticholic Acid (OCA), Elafibranor and Selonsertib &
Cenicriviroc - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR
Table 71: Italy Historic Review for Non-alcoholic
Steatohepatitis (NASH) by Drug Type - Vitamin E & Pioglitazone,
Obeticholic Acid (OCA), Elafibranor and Selonsertib &
Cenicriviroc Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2012 through 2019 and % CAGR
Table 72: Italy 15-Year Perspective for Non-alcoholic
Steatohepatitis (NASH) by Drug Type - Percentage Breakdown of
Value Sales for Vitamin E & Pioglitazone, Obeticholic Acid
(OCA), Elafibranor and Selonsertib & Cenicriviroc for the Years
2012, 2020 & 2027
Table 73: Italy Current & Future Analysis for Non-alcoholic
Steatohepatitis (NASH) by Sales Channel - Hospital Pharmacy,
Online Provider and Retail Pharmacy - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR
Table 74: Italy Historic Review for Non-alcoholic
Steatohepatitis (NASH) by Sales Channel - Hospital Pharmacy,
Online Provider and Retail Pharmacy Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR
Table 75: Italy 15-Year Perspective for Non-alcoholic
Steatohepatitis (NASH) by Sales Channel - Percentage Breakdown
of Value Sales for Hospital Pharmacy, Online Provider and
Retail Pharmacy for the Years 2012, 2020 & 2027
UNITED KINGDOM
Table 76: UK Current & Future Analysis for Non-alcoholic
Steatohepatitis (NASH) by Drug Type - Vitamin E & Pioglitazone,
Obeticholic Acid (OCA), Elafibranor and Selonsertib &
Cenicriviroc - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR
Table 77: UK Historic Review for Non-alcoholic Steatohepatitis
(NASH) by Drug Type - Vitamin E & Pioglitazone, Obeticholic
Acid (OCA), Elafibranor and Selonsertib & Cenicriviroc Markets -
Independent Analysis of Annual Sales in US$ Thousand for
Years 2012 through 2019 and % CAGR
Table 78: UK 15-Year Perspective for Non-alcoholic
Steatohepatitis (NASH) by Drug Type - Percentage Breakdown of
Value Sales for Vitamin E & Pioglitazone, Obeticholic Acid
(OCA), Elafibranor and Selonsertib & Cenicriviroc for the Years
2012, 2020 & 2027
Table 79: UK Current & Future Analysis for Non-alcoholic
Steatohepatitis (NASH) by Sales Channel - Hospital Pharmacy,
Online Provider and Retail Pharmacy - Independent Analysis of
Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR
Table 80: UK Historic Review for Non-alcoholic Steatohepatitis
(NASH) by Sales Channel - Hospital Pharmacy, Online Provider
and Retail Pharmacy Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Table 81: UK 15-Year Perspective for Non-alcoholic
Steatohepatitis (NASH) by Sales Channel - Percentage Breakdown
of Value Sales for Hospital Pharmacy, Online Provider and
Retail Pharmacy for the Years 2012, 2020 & 2027
REST OF EUROPE
Table 82: Rest of Europe Current & Future Analysis for
Non-alcoholic Steatohepatitis (NASH) by Drug Type - Vitamin E &
Pioglitazone, Obeticholic Acid (OCA), Elafibranor and
Selonsertib & Cenicriviroc - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 and %
CAGR
Table 83: Rest of Europe Historic Review for Non-alcoholic
Steatohepatitis (NASH) by Drug Type - Vitamin E & Pioglitazone,
Obeticholic Acid (OCA), Elafibranor and Selonsertib &
Cenicriviroc Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2012 through 2019 and % CAGR
Table 84: Rest of Europe 15-Year Perspective for Non-alcoholic
Steatohepatitis (NASH) by Drug Type - Percentage Breakdown of
Value Sales for Vitamin E & Pioglitazone, Obeticholic Acid
(OCA), Elafibranor and Selonsertib & Cenicriviroc for the Years
2012, 2020 & 2027
Table 85: Rest of Europe Current & Future Analysis for
Non-alcoholic Steatohepatitis (NASH) by Sales Channel -
Hospital Pharmacy, Online Provider and Retail Pharmacy -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR
Table 86: Rest of Europe Historic Review for Non-alcoholic
Steatohepatitis (NASH) by Sales Channel - Hospital Pharmacy,
Online Provider and Retail Pharmacy Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR
Table 87: Rest of Europe 15-Year Perspective for Non-alcoholic
Steatohepatitis (NASH) by Sales Channel - Percentage Breakdown
of Value Sales for Hospital Pharmacy, Online Provider and
Retail Pharmacy for the Years 2012, 2020 & 2027
ASIA-PACIFIC
Table 88: Asia-Pacific Current & Future Analysis for
Non-alcoholic Steatohepatitis (NASH) by Drug Type - Vitamin E &
Pioglitazone, Obeticholic Acid (OCA), Elafibranor and
Selonsertib & Cenicriviroc - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 and %
CAGR
Table 89: Asia-Pacific Historic Review for Non-alcoholic
Steatohepatitis (NASH) by Drug Type - Vitamin E & Pioglitazone,
Obeticholic Acid (OCA), Elafibranor and Selonsertib &
Cenicriviroc Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2012 through 2019 and % CAGR
Table 90: Asia-Pacific 15-Year Perspective for Non-alcoholic
Steatohepatitis (NASH) by Drug Type - Percentage Breakdown of
Value Sales for Vitamin E & Pioglitazone, Obeticholic Acid
(OCA), Elafibranor and Selonsertib & Cenicriviroc for the Years
2012, 2020 & 2027
Table 91: Asia-Pacific Current & Future Analysis for
Non-alcoholic Steatohepatitis (NASH) by Sales Channel -
Hospital Pharmacy, Online Provider and Retail Pharmacy -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR
Table 92: Asia-Pacific Historic Review for Non-alcoholic
Steatohepatitis (NASH) by Sales Channel - Hospital Pharmacy,
Online Provider and Retail Pharmacy Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR
Table 93: Asia-Pacific 15-Year Perspective for Non-alcoholic
Steatohepatitis (NASH) by Sales Channel - Percentage Breakdown
of Value Sales for Hospital Pharmacy, Online Provider and
Retail Pharmacy for the Years 2012, 2020 & 2027
REST OF WORLD
Table 94: Rest of World Current & Future Analysis for
Non-alcoholic Steatohepatitis (NASH) by Drug Type - Vitamin E &
Pioglitazone, Obeticholic Acid (OCA), Elafibranor and
Selonsertib & Cenicriviroc - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 and %
CAGR
Table 95: Rest of World Historic Review for Non-alcoholic
Steatohepatitis (NASH) by Drug Type - Vitamin E & Pioglitazone,
Obeticholic Acid (OCA), Elafibranor and Selonsertib &
Cenicriviroc Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2012 through 2019 and % CAGR
Table 96: Rest of World 15-Year Perspective for Non-alcoholic
Steatohepatitis (NASH) by Drug Type - Percentage Breakdown of
Value Sales for Vitamin E & Pioglitazone, Obeticholic Acid
(OCA), Elafibranor and Selonsertib & Cenicriviroc for the Years
2012, 2020 & 2027
Table 97: Rest of World Current & Future Analysis for
Non-alcoholic Steatohepatitis (NASH) by Sales Channel -
Hospital Pharmacy, Online Provider and Retail Pharmacy -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR
Table 98: Rest of World Historic Review for Non-alcoholic
Steatohepatitis (NASH) by Sales Channel - Hospital Pharmacy,
Online Provider and Retail Pharmacy Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR
Table 99: Rest of World 15-Year Perspective for Non-alcoholic
Steatohepatitis (NASH) by Sales Channel - Percentage Breakdown
of Value Sales for Hospital Pharmacy, Online Provider and
Retail Pharmacy for the Years 2012, 2020 & 2027
IV. COMPETITION
Total Companies Profiled: 41
Read the full report: https://www.reportlinker.com/p06044755/?utm_source=GNW
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
__________________________